Tadocizumab (Anti-Integrin a2b3 (ITGA2 & ITGB3)) is a humanized monoclonal antibody tageting integrin αIIbβ3. It has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research. MW :145.3 KD.